Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1997;75(7):986–992. doi: 10.1038/bjc.1997.170

Comparative pharmacokinetic and cytotoxic analysis of three different formulations of mitoxantrone in mice.

K M Rentsch 1, D H Horber 1, R A Schwendener 1, H Wunderli-Allenspach 1, E Hänseler 1
PMCID: PMC2222749  PMID: 9083333

Abstract

Two liposomal formulations of mitoxantrone (MTO) were compared with the aqueous solution (free MTO) in terms of their pharmacokinetic behaviour in ICR mice and cytotoxic activity in a nude mouse xenograft model. The three different formulations of MTO [free MTO, phosphatidic acid (PA)-MTO liposomes, pH-MTO liposomes] were administered intravenously (three mice per formulation and time point) at a dose of 4.7 micromol kg(-1) for free MTO, 6.1 micromol kg(-1) for PA-MTO and 4.5 micromol kg(-1) for pH-MTO. The concentrations of MTO were determined using high-performance liquid chromatography (HPLC) in blood, liver, heart, spleen and kidneys of the mice. Additionally, the toxicity and anti-tumour activity of MTO was evaluated in a xenograft model using a human LXFL 529/6 large-cell lung carcinoma. The dose administered was 90% of the maximum tolerated dose (MTD) of the corresponding formulation (8.1 micromol kg(-1) for free MTO, 12.1 micromol kg(-1) for PA-MTO and pH-MTO). The pharmacokinetic behaviour of PA-MTO in blood was faster than that of free MTO, but the cytotoxic effect was improved. In contrast, pH-MTO showed a tenfold increased area under the curve (AUC) in blood compared with free MTO, without improvement of the cytotoxic effect. This discrepancy between the pharmacokinetic and cytotoxic results could be explained by the fact that MTO in pH-MTO liposomes remains mainly in the vascular space, whereas MTO in PA-MTO liposomes is rapidly distributed into deep compartments, even more so than free MTO.

Full text

PDF
986

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alberts D. S., Peng Y. M., Bowden G. T., Dalton W. S., Mackel C. Pharmacology of mitoxantrone: mode of action and pharmacokinetics. Invest New Drugs. 1985;3(2):101–107. doi: 10.1007/BF00174156. [DOI] [PubMed] [Google Scholar]
  2. Alberts D. S., Peng Y. M., Leigh S., Davis T. P., Woodward D. L. Disposition of mitoxantrone in cancer patients. Cancer Res. 1985 Apr;45(4):1879–1884. [PubMed] [Google Scholar]
  3. Amselem S., Gabizon A., Barenholz Y. Optimization and upscaling of doxorubicin-containing liposomes for clinical use. J Pharm Sci. 1990 Dec;79(12):1045–1052. doi: 10.1002/jps.2600791202. [DOI] [PubMed] [Google Scholar]
  4. Batra V. K., Morrison J. A., Woodward D. L., Siverd N. S., Yacobi A. Pharmacokinetics of mitoxantrone in man and laboratory animals. Drug Metab Rev. 1986;17(3-4):311–329. doi: 10.3109/03602538608998294. [DOI] [PubMed] [Google Scholar]
  5. Blanz J., Mewes K., Ehninger G., Proksch B., Waidelich D., Greger B., Zeller K. P. Evidence for oxidative activation of mitoxantrone in human, pig, and rat. Drug Metab Dispos. 1991 Sep-Oct;19(5):871–880. [PubMed] [Google Scholar]
  6. DuKart G., Iatropoulos M. J., Yacobi A. Comment on mitoxantrone. Drug Intell Clin Pharm. 1985 Mar;19(3):216–218. doi: 10.1177/106002808501900317. [DOI] [PubMed] [Google Scholar]
  7. Faulds D., Balfour J. A., Chrisp P., Langtry H. D. Mitoxantrone. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the chemotherapy of cancer. Drugs. 1991 Mar;41(3):400–449. doi: 10.2165/00003495-199141030-00007. [DOI] [PubMed] [Google Scholar]
  8. Forssen E. A., Coulter D. M., Proffitt R. T. Selective in vivo localization of daunorubicin small unilamellar vesicles in solid tumors. Cancer Res. 1992 Jun 15;52(12):3255–3261. [PubMed] [Google Scholar]
  9. Gabizon A. A., Barenholz Y., Bialer M. Prolongation of the circulation time of doxorubicin encapsulated in liposomes containing a polyethylene glycol-derivatized phospholipid: pharmacokinetic studies in rodents and dogs. Pharm Res. 1993 May;10(5):703–708. doi: 10.1023/a:1018907715905. [DOI] [PubMed] [Google Scholar]
  10. Gabizon A. A. Selective tumor localization and improved therapeutic index of anthracyclines encapsulated in long-circulating liposomes. Cancer Res. 1992 Feb 15;52(4):891–896. [PubMed] [Google Scholar]
  11. Khor S. P., Mayersohn M. Potential error in the measurement of tissue to blood distribution coefficients in physiological pharmacokinetic modeling. Residual tissue blood. I. Theoretical considerations. Drug Metab Dispos. 1991 Mar-Apr;19(2):478–485. [PubMed] [Google Scholar]
  12. Lasic D. D., Martin F. J., Gabizon A., Huang S. K., Papahadjopoulos D. Sterically stabilized liposomes: a hypothesis on the molecular origin of the extended circulation times. Biochim Biophys Acta. 1991 Nov 18;1070(1):187–192. doi: 10.1016/0005-2736(91)90162-2. [DOI] [PubMed] [Google Scholar]
  13. Liliemark J., Peterson C. Pharmacokinetic optimisation of anticancer therapy. Clin Pharmacokinet. 1991 Sep;21(3):213–231. doi: 10.2165/00003088-199121030-00005. [DOI] [PubMed] [Google Scholar]
  14. Madden T. D., Harrigan P. R., Tai L. C., Bally M. B., Mayer L. D., Redelmeier T. E., Loughrey H. C., Tilcock C. P., Reinish L. W., Cullis P. R. The accumulation of drugs within large unilamellar vesicles exhibiting a proton gradient: a survey. Chem Phys Lipids. 1990 Mar;53(1):37–46. doi: 10.1016/0009-3084(90)90131-a. [DOI] [PubMed] [Google Scholar]
  15. Mayer L. D., Bally M. B., Cullis P. R. Uptake of adriamycin into large unilamellar vesicles in response to a pH gradient. Biochim Biophys Acta. 1986 May 9;857(1):123–126. doi: 10.1016/0005-2736(86)90105-7. [DOI] [PubMed] [Google Scholar]
  16. Mayer L. D., Bally M. B., Hope M. J., Cullis P. R. Uptake of antineoplastic agents into large unilamellar vesicles in response to a membrane potential. Biochim Biophys Acta. 1985 Jun 27;816(2):294–302. doi: 10.1016/0005-2736(85)90497-3. [DOI] [PubMed] [Google Scholar]
  17. Mayhew E. G., Lasic D., Babbar S., Martin F. J. Pharmacokinetics and antitumor activity of epirubicin encapsulated in long-circulating liposomes incorporating a polyethylene glycol-derivatized phospholipid. Int J Cancer. 1992 May 8;51(2):302–309. doi: 10.1002/ijc.2910510221. [DOI] [PubMed] [Google Scholar]
  18. Rahman A., Ganjei A., Neefe J. R. Comparative immunotoxicity of free doxorubicin and doxorubicin encapsulated in cardiolipin liposomes. Cancer Chemother Pharmacol. 1986;16(1):28–34. doi: 10.1007/BF00255282. [DOI] [PubMed] [Google Scholar]
  19. Rentsch K. M., Schwendener R. A., Hänseler E. Determination of mitoxantrone in mouse whole blood and different tissues by high-performance liquid chromatography. J Chromatogr B Biomed Appl. 1996 Apr 26;679(1-2):185–192. doi: 10.1016/0378-4347(96)00023-0. [DOI] [PubMed] [Google Scholar]
  20. Roboz J., Paciucci P. A., Silides D., Greaves J., Holland J. F. Detection and quantification of mitoxantrone in human organs. A case report. Cancer Chemother Pharmacol. 1984;13(1):67–68. doi: 10.1007/BF00401451. [DOI] [PubMed] [Google Scholar]
  21. Rubas W., Supersaxo A., Weder H. G., Hartmann H. R., Hengartner H., Schott H., Schwendener R. Treatment of murine L1210 lymphoid leukemia and melanoma B16 with lipophilic cytosine arabinoside prodrugs incorporated into unilamellar liposomes. Int J Cancer. 1986 Jan 15;37(1):149–154. doi: 10.1002/ijc.2910370123. [DOI] [PubMed] [Google Scholar]
  22. Schwendener R. A., Fiebig H. H., Berger M. R., Berger D. P. Evaluation of incorporation characteristics of mitoxantrone into unilamellar liposomes and analysis of their pharmacokinetic properties, acute toxicity, and antitumor efficacy. Cancer Chemother Pharmacol. 1991;27(6):429–439. doi: 10.1007/BF00685156. [DOI] [PubMed] [Google Scholar]
  23. Shenkenberg T. D., Von Hoff D. D. Mitoxantrone: a new anticancer drug with significant clinical activity. Ann Intern Med. 1986 Jul;105(1):67–81. doi: 10.7326/0003-4819-105-1-67. [DOI] [PubMed] [Google Scholar]
  24. Stewart D. J., Green R. M., Mikhael N. Z., Montpetit V., Thibault M., Maroun J. A. Human autopsy tissue concentrations of mitoxantrone. Cancer Treat Rep. 1986 Nov;70(11):1255–1261. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES